UPS Spends $50 Million on GLP-1 Cold Storage

UPS is putting $48 million into 27 temperature-controlled facilities, a bet sized to capture share of a $39.1 billion temperature-sensitive biologics market that keeps expanding as cold-storage medications become standard. The Monday announcement signals where the freight major now sees its most durable growth: healthcare logistics.

At a Glance

• UPS is investing $48 million across 27 global temperature-controlled sites for short-term storage between air and ground legs.
• The target market for temperature-sensitive biologics is valued at $39.1 billion and growing.
• Improper storage drives 50% of global vaccine waste, costing $35 billion annually, per the WHO.
• UPS's healthcare portfolio cleared $3 billion in quarterly revenue for the first time in Q1.
• FedEx closed fiscal 2024 with roughly $9 billion in healthcare revenue and is expanding its pharma offering.

Reading the $48 million bet

Break down the math and the logic is straightforward. Twenty-seven facilities, $48 million, works out to modest capital per site, which fits their stated purpose: short-term holding points that bridge air and ground transportation rather than full distribution warehouses. The investment is less about building bulk capacity and more about closing temperature-control gaps in the existing network, the points where cold-chain integrity tends to break.

That focus tracks with where the money would be lost otherwise. The World Health Organization attributes half of all global vaccine waste to temperature excursions, a problem that carries a $35 billion annual price tag. Every facility that holds product within spec between transport modes is a hedge against that loss. For a carrier moving gene and cell therapies, mRNA vaccines, and GLP-1 injectables, the cost of a single failed shipment dwarfs the per-site capital outlay.

Kate Gutmann, who runs international, healthcare and supply chain solutions at UPS, framed the expansion around patient outcomes rather than throughput. The commercial reasoning underneath is harder-edged: high-value, fragile cargo commands premium handling rates, and demand is climbing.

Why GLP-1 demand is reshaping the cold chain

The single clearest driver is GLP-1 medication. KFF data from November 2025 shows one in eight adults reporting use of a GLP-1, whether for diabetes, weight loss, or another indication. That penetration rate is unusual for a drug class, and it translates directly into shipment volume for products that must stay cold from factory to pharmacy.

Manufacturers are scaling to match. Eli Lilly said in March it would commit $3 billion over the next decade to expand manufacturing in China, with much of that capacity earmarked for orforglipron, its experimental GLP-1 receptor candidate. More production means more units moving through temperature-controlled lanes.

Policy is adding to the pull. Starting July 1, a Centers for Medicare & Medicaid Services initiative may let Medicare beneficiaries access some GLP-1 prescriptions for $50 a month. Lower out-of-pocket cost typically lifts utilization, which feeds back into shipping volume. Carriers building cold-chain capacity now are positioning ahead of that demand curve, not reacting to it.

The inelasticity argument

UPS leadership has been explicit about why healthcare is the priority. CEO Carol Tome told Reuters in April that the segment kept growing through a stretch of high inflation and market contractions, and called it "pretty recession-proof." The economic case rests on inelastic demand: patients pursue treatment regardless of the macro environment, so the revenue holds up when discretionary freight softens.

For a parcel network exposed to consumer and industrial shipping cycles, that stability is the point. Healthcare gives UPS a counterweight to volumes that swing with the economy. The numbers back the thesis. Tome said on the first-quarter earnings call that the global healthcare portfolio has taken market share every year since 2021 and generated $3 billion in revenue last quarter, a first for the unit.

Buying the cold chain, not just building it

The $48 million in greenfield-style capacity is one leg of a broader acquisition push. UPS has been buying specialized cold-chain operators outright to accelerate the pivot:

• November 2025: acquisition of Andlauer Healthcare Group for $1.6 billion.
• January: acquisition of Frigo-Trans and BPL, European cold-chain healthcare logistics specialists.
• Ongoing: the 27-facility temperature-controlled buildout announced this week.

The pattern is deliberate. Rather than assemble cold-chain expertise from scratch, UPS is folding in established operators with the certifications, validated processes, and customer relationships that pharma shippers demand. Quality compliance in this space is a barrier to entry, and buying it is faster than building it.

FedEx runs the same playbook

The competitive read matters here, because UPS is not alone. FedEx is pursuing a parallel strategy and closed fiscal 2024 with about $9 billion in healthcare revenue, well ahead of the UPS figure. Earlier this year FedEx brought on a healthcare-focused vice president of quality with global logistics experience, a hire that signals where it wants to grow.

FedEx Chief Customer Officer Brie Carere told investors in March the company is under-penetrated in pharma and is upgrading its offering to meet the specialized needs of those customers, with heavy emphasis on quality. The language mirrors the UPS thesis almost exactly: chase the regulated, high-margin pharma business by leading with compliance.

What the figures imply

Set the pieces side by side and the direction is unambiguous. A $39.1 billion addressable market, $35 billion in annual waste from temperature failures, GLP-1 penetration at one in eight adults, and a Medicare price change that could widen access further. Against that backdrop, $48 million for 27 staging facilities reads as a small, targeted move within a much larger capital commitment that already includes a $1.6 billion acquisition.

The strategic question is no longer whether freight carriers want pharma volume. Both UPS and FedEx have answered that. The contest is over quality validation and network density in cold-chain handling, the two things pharmaceutical shippers weigh most heavily. UPS's facility buildout and acquisition spree are aimed squarely at both.

Frequently Asked Questions

How much is UPS investing in temperature-controlled facilities?

UPS is investing $48 million in 27 temperature-controlled facilities worldwide. The sites handle short-term storage as shipments move between air and ground transportation.

How big is the temperature-sensitive biologics market?

The temperature-sensitive biologics market is valued at $39.1 billion and continues to grow as demand rises for medications that must be stored cold, including gene and cell therapies, mRNA vaccines, and GLP-1 injectables.

Why are freight companies prioritizing healthcare logistics?

Healthcare demand is largely inelastic, so it holds up through downturns when other shipping volumes fall. UPS CEO Carol Tome has described healthcare as "pretty recession-proof," and the segment has gained market share for the carrier every year since 2021.

How does FedEx compare to UPS in healthcare?

FedEx ended fiscal 2024 with about $9 billion in healthcare revenue and has hired a healthcare-focused vice president of quality. It describes itself as under-penetrated in pharma and is upgrading its offering to win that business.

The outlook

With manufacturers scaling GLP-1 production, a Medicare price change set for July 1, and biologics demand structurally rising, the cold-chain segment looks set to keep growing faster than parcel volumes overall. UPS has tied real capital to that view. FedEx has matched the intent if not yet the same moves. Expect the rivalry to be fought on quality credentials and how tightly each network can hold temperature across every leg of a shipment.